RxDoctor Payments Data

Dina White, MD

Family Medicine · Sugarland, TXNPI 1922061548

Payments from drug & device makers

$7,392in general payments, 2019–2025

Across 430 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$804
  • Amgen$695
  • GSK$633
  • Lilly USA, LLC$571
  • AstraZeneca$421
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,26598%
  • Education$1282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,392 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$175,012
Medicare patients
281
Services billed
3,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$110,516
MounjaroTirzepatide40$46,172
TrulicityDulaglutide20$37,459
JardianceEmpagliflozin28$34,562
FarxigaDapagliflozin Propanediol20$27,709
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,359
VraylarCariprazine Hcl13$18,288
VascepaIcosapent Ethyl29$17,780
Synjardy XrEmpagliflozin/Metformin Hcl12$16,483
EliquisApixaban12$15,880
Breo ElliptaFluticasone/Vilanterol13$6,777
LinzessLinaclotide12$6,751
Rosuvastatin Calcium370$4,350
SynthroidLevothyroxine Sodium50$4,289
Levothyroxine Sodium271$3,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$804$110,51676 claims
Lilly USA, LLCMounjaro, Trulicity$571$83,63260 claims
Boehringer IngelheimJardiance, Synjardy Xr$173$51,04540 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$633$30,57047 claims
AbbVieVraylar, Linzess, Synthroid$1,089$29,32975 claims
AstraZenecaFarxiga$421$27,70920 claims
PfizerEliquis, Paxlovid$262$17,24823 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$3,675271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugarland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →